Back to top

Image: Bigstock

Merck Ends Nemtabrutinib Development: What's Next for Its Pipeline?

Read MoreHide Full Article

Key Takeaways

  • Merck discontinues the BELLWAVE program evaluating nemtabrutinib for hematologic malignancies.
  • An external committee found the potential benefits may not outweigh the risks in the phase III study.
  • MRK sees over $70 billion in potential pipeline opportunities by the mid-2030s, with estimates likely to rise.

Merck (MRK - Free Report) has made considerable progress in advancing the pipeline, particularly in areas like oncology, vaccines and infectious diseases, where it is developing several candidates with the potential to diversify the portfolio and expand the revenue base.

MRK’s phase III pipeline has almost tripled since 2021, supported by in-house pipeline progress as well as the addition of candidates through various merger and acquisition deals. The company expects to launch 20 new drugs by 2030, with many already launched carrying blockbuster potential.

However, yesterday, Merck faced a setback in its hematology pipeline after announcing the discontinuation of the BELLWAVE clinical development program evaluating nemtabrutinib (MK-1026). An investigational oral, non-covalent Bruton's tyrosine kinase inhibitor, nemtabrutinib, is being developed to treat patients with chronic lymphocytic leukemia, small lymphocytic lymphoma and other hematologic malignancies.

The decision follows a review of the phase III BELLWAVE-011 study by an external Data Monitoring Committee, which suggested that the potential benefits may not outweigh the risks. Subsequently, Merck confirmed this assessment after reviewing the complete data and decided to discontinue the broader BELLWAVE program, including the phase III BELLWAVE-008 and BELLWAVE-010 studies on nemtabrutinib.

MRK’s Broader Pipeline Holds Promise

Although the discontinuation of the nemtabrutinib program is a setback for Merck's hematology pipeline, its progress across the broader pipeline and various disease areas remains promising.

Key late-stage candidates include sacituzumab tirumotecan (sac-TMT), an anti-TROP2 antibody-drug conjugate for multiple tumor types, MK-8591D/islatravir plus lenacapavir, a once-weekly oral treatment for HIV, and alimatravir, a monthly oral HIV PrEP candidate. Another promising candidate is tulisokibart, an investigational TL1A inhibitor being developed for various immunology indications. Merck is also advancing intismeran autogene (V940), a personalized cancer therapy, being developed in collaboration with Moderna (MRNA - Free Report) .

Moderna is working with Merck to submit a regulatory filing with the FDA for intismeran autogene by year-end 2026. The regulatory filing will be supported by positive results from the phase III INTerpath-001 study, which evaluated intismeran plus Keytruda in patients with high-risk (Stage IIB-IV) melanoma whose tumors had been surgically removed.

Merck expects more than $70 billion of potential non-risk-adjusted commercial opportunity for the current pipeline by the mid-2030s. This estimate is more than double the peak consensus sales estimate for Keytruda of $35 billion in 2028.

The company has also stepped-up acquisitions ahead of Keytruda’s 2028 patent expiry. Recent deals added Ohtuvayre through Verona Pharma, influenza candidate MK-1406 through Cidara and potential blockbuster cancer drug MK-4208 through Terns Pharmaceuticals.

On the third-quarter conference call, Merck mentioned that it expects to raise the $70 billion mid-2030s revenue opportunity estimate, driven by growing confidence in the pipeline, additional revenue potential from the Terns acquisition, PD-1/VEGF combinations, broader indications for sac-TMT and stronger-than-expected commercial prospects for intismeran.

PD-1/PD-L1 Inhibitors Competing With MRK's Keytruda

Merck’s blockbuster PD-1 inhibitor, Keytruda, faces competition from other PD-1/PD-L1 inhibitors, including Bristol Myers’ (BMY - Free Report) Opdivo, Roche’s (RHHBY - Free Report) Tecentriq and AstraZeneca’s Imfinzi.

BMY’s Opdivo, also a PD-1 inhibitor like Keytruda, is approved across multiple cancer types, including lung, melanoma and kidney cancers. Bristol Myers recorded $7 billion in Opdivo sales in the first nine months of 2026, down 5% year over year.

Tecentriq is Roche’s leading immuno-oncology drug approved for multiple cancer indications. RHHBY recorded CHF 2.6 billion in Tecentriq sales in the first nine months of 2026, up 5% year over year.

AstraZeneca’s Imfinzi generated $5.5 billion in sales in the first nine months of 2026, up 28% year over year, driven by strong demand growth across all regions from established indications and new launches.

MRK’s Share Price, Valuation & Estimates

Year to date, shares of Merck have rallied 39% compared with the industry’s 28.1% rise.

Zacks Investment Research
Image Source: Zacks Investment Research

From a valuation standpoint, Merck appears to be trading at a discount compared with the industry. Going by the price/earnings ratio, MRK’s shares currently trade at 17.19 forward earnings, lower than 19.71 for the industry. The stock is also trading above its five-year mean of 13.29.

Zacks Investment Research
Image Source: Zacks Investment Research

Estimates for MRK’s 2026 earnings per share have risen from $2.66 to $2.78 over the past 30 days, while those for 2027 have declined from $9.27 to $9.08.

Zacks Investment Research
Image Source: Zacks Investment Research

MRK’s Zacks Rank

Merck currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Published in